Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 2/20 | 0.37 |
| ▸ | ADH1C | P00326 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.31 |
| ▸ | XBP1 | P17861 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11113407 | 0.79 | ADH1A (0.41) | ADH1AADH1CNPSR1L3MBTL1MEN1 | |
| SCHEMBL1902755 | 0.75 | ADRA2A (0.42) | ADH1AADH1CNPSR1ADRA2APDE4A | |
| SCHEMBL14776360 | 0.74 | ADH1C (0.35) | ADH1AADH1CNPSR1MEN1KMT2A | |
| SCHEMBL701945 | 0.73 | ADRA2A (0.40) | ADH1AADH1CNPSR1ADRA2APDE4A | |
| SCHEMBL102987 | 0.72 | LMNA (0.36) | ADH1AADH1CNPSR1ADRA2APDE4A | |
| SCHEMBL1902754 | 0.72 | ADH1C (0.33) | ADH1AADH1CALDH1A1TSHRS1PR1 | |
| SCHEMBL6467646 | 0.71 | EPHX1 (0.42) | ADH1AADH1CADRA2APDE4AADRA1A | |
| SCHEMBL14791027 | 0.70 | LMNA (0.37) | ADH1AADH1CNPSR1ADRA2APDE4A | |
| SCHEMBL1238560 | 0.69 | ALOX5 (0.39) | ADH1AADH1CADRA2APDE4AADRA1A | |
| SCHEMBL39462 | 0.68 | ADRA2A (0.40) | ADH1AADH1CADRA2APDE4AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2673362-B1 | PLEXIN-B1 ANTAGONISTS AND USES THEREOF | Ruprecht-Karls-Universität Heidelberg (DE) | 2017-06-07 | — | — | EP | claimed |
| CN-114558032-A | Method for preparing platelets from pluripotent stem cells and composition thereof | 安斯泰来再生医药协会 | 2022-05-31 | — | — | CN | disclosed |
| CN-105101979-B | Method for preparing platelets from pluripotent stem cells and composition thereof | 安斯泰来再生医药协会 | 2021-10-08 | — | — | CN | disclosed |
| EP-3191114-B1 | OCCIDIOFUNGIN FORMULATIONS AND USES THEREOF | UNIV MISSISSIPPI STATE (US) | 2021-03-03 | — | — | EP | disclosed |
| US-10265374-B2 | Occidiofungin formations and uses thereof | MISSISSIPPI STATE UNIVERSITY (US) | 2019-04-23 | — | — | US | disclosed |
| US-20170281721-A1 | OCCIDIOFUNGIN FORMATIONS AND USES THEREOF | MISSISSIPPI STATE UNIVERSITY (US) | 2017-10-05 | — | — | US | disclosed |
| EP-3191114-A1 | OCCIDIOFUNGIN FORMULATIONS AND USES THEREOF | Smith, James (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016040940-A1 | OCCIDIOFUNGIN FORMULATIONS AND USES THEREOF | AUSTIN, FRANK (US) | 2016-03-17 | — | — | WO | disclosed |
| US-8476246-B2 | Combination of a chemotherapeutic agent and an inhibitor of the TGF-beta system | ANTISENSE PHARMA GMBH (DE) | 2013-07-02 | — | — | US | disclosed |
| US-20120142722-A1 | CONJUGATES OF CYTOTOXIC DRUGS | APOSENSE LTD. (IL) | 2012-06-07 | — | — | US | disclosed |
| US-6949350-B1 | Chemosensitivity determination using phosphatidylserine | EVOTEC ANALYTICAL SYSTEMS GMBH (DE) | 2005-09-27 | — | — | US | disclosed |
| US-20050203082-A1 | Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents | PHARMACIA CORPORATION | 2005-09-15 | — | — | US | disclosed |
| WO-2005059133-A2 | COMBINATION THERAPY ASSOCIATING A TGF-BRETA ANTAGONIST WITH A CHEMIOTHERAPEUTIC AGENT | ANTISENSE PHARMA GMBH (DE) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005025620-A2 | COMBINATION THERAPY WITH INHIBITORS OF INDUCIBLE NITRIC OXIDE SYNTHASE AND ALKYLATING AGENTS | PHARMACIA CORPORATION (US) | 2005-03-24 | — | — | WO | disclosed |
| US-5736129-A | Flow cytometric pharmacosensitivity assay and method of cancer treatment | SHAKER CORPORATION, A DELAWARE CORPORATION | 1998-04-07 | — | — | US | disclosed |
| WO-1997019189-A1 | FLOW CYTOMETRIC PHARMACOSENSITIVITY ASSAY AND METHOD OF CANCER TREATMENT | MEDENICA RAJKO D (US) | 1997-05-29 | — | — | WO | disclosed |
| EP-0525188-B1 | LIPOSOME COMPOSITION | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-03-01 | — | — | EP | disclosed |
| US-5252336-A | Good dispersibility; high stability; high encapsulation properties | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-10-12 | — | — | US | disclosed |
| EP-0525188-A1 | LIPOSOME COMPOSITION. | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1993-02-03 | — | — | EP | disclosed |
| WO-1991016040-A1 | LIPOSOME COMPOSITION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203082-A1 | Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents | NOS2, NOS1, NOS3 | ADH1A 1360/4885ADH1C 1600/4885NPSR1 3888/4885 |
| US-20120142722-A1 | CONJUGATES OF CYTOTOXIC DRUGS | CD47, MCL1, BAD | ADH1A 4313/4885ADH1C 4328/4885NPSR1 3013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.